IAM
APLS

Innovis Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Innovis Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$477K Buy
+12,535
New +$551K 0.18% 70

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Innovis Asset Management's APLS Position: Q3 2023 in Review

Innovis Asset Management opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2023: 12,535 shares worth $477K. The stake represents 0.18% of the portfolio and ranks #70 among its holdings.

256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Innovis Asset Management held 12,535 shares of Apellis Pharmaceuticals worth $477K as of Q3 2023.
  • Apellis Pharmaceuticals was a new Innovis Asset Management position in Q3 2023.
  • Apellis Pharmaceuticals made up 0.18% of Innovis Asset Management's portfolio in Q3 2023, its #70 holding.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.